The frontline induction treatment of bendamustine and rituximab (Rituxan; BR) has improved event-free survival (EFS) compared with R-CHOP therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with mantle cell lymphoma (MCL), according to an analysis of real-world data presented at the 2018 ASH Annual Meeting.
“While patterns of care in MCL continue to evolve, the introduction of bendamustine and high-dose cytarabine-based regimens resulted in an improvement in EFS but not OS in this observational cohort-based analysis,” the investigators concluded.
Castellino A, Larson MC, Maurer MJ, et al. Patterns of care and outcomes in mantle cell lymphoma in the modern immunochemotherapy era. Presented at: 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 4140.
... to read the full story